# US 2020/0399644 A1 · Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2020/0399644 A1 - Document ID: US20200399644A1 - Status: Published application - Kind: A1 - Application number: 16/842,054 - Filed: 2020-04-07 - Published: 2020-12-24 - Earliest claimed: 2010-01-28 - Assignees: The Board of Trustees of the Leland Stanford Junior University; The United States Government as represented by the Department of Veterans Affairs - Applicants: The Board of Trustees of the Leland Stanford Junior University; The United States Government AS Represented By the Department of Veterans Affairs - Inventors: Anton Wyss-Coray; Thomas A. Rando; Markus Britschgi; Kaspar Rufibach; Saul A. Villeda - Web page: https://patentgrep.com/patent/US20200399644A1 ## CPC - C12N 15/1138: {against receptors or cell surface proteins} - A61K 31/00: Medicinal preparations containing organic active ingredients - A61K 31/7088: Compounds having three or more nucleosides or nucleotides - A61K 38/19: Cytokines; Lymphokines; Interferons - A61K 38/45: Transferases (2) - C07K 16/24: against cytokines, lymphokines or interferons - C07K 16/28: against receptors, cell surface antigens or cell surface determinants - C12Q 1/6883: for diseases caused by alterations of genetic material - A61K 2039/505: {comprising antibodies} - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C12N 2310/14: interfering nucleic acids [NA] - C12N 2799/022: where the vector is derived from an adenovirus - C12N 2799/06: in vitro - C12Q 2600/136: Screening for pharmacological compounds - C12Q 2600/158: Expression markers - C12Y 207/10001: Receptor protein-tyrosine kinase (2.7.10.1) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - C12Y: ENZYMES ## Abstract Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments. ## Claims ### Claim 1 A method of treating an adult mammal for an aging-associated impairment, the method comprising: modulating CCR3 in the mammal in a manner sufficient to treat the adult mammal for the aging-associated impairment. ### Claim 2 (depends on 1) The method according to claim 1, wherein modulating CCR3 comprises modulating eotaxin-1/CCR3 interaction. ### Claim 3 (depends on 2) The method according to claim 2, wherein eotaxin-1/CCR3 interaction is modulated by reducing active systemic eotaxin-1 in the mammal. ### Claim 4 (depends on 3) The method according to claim 3, wherein the active systemic eotaxin-1 is reduced in the mammal by administering to the mammal an effective amount of an active systemic eotaxin-1 reducing agent. ### Claim 5 (depends on 4) The method according to claim 4, wherein the active systemic eotaxin-1 reducing agent is an eotaxin-1 binding agent. ### Claim 6 (depends on 5) The method according to claim 5, wherein the eotaxin-1 binding agent comprises an antibody or binding fragment thereof. ### Claim 7 (depends on 5) The method according to claim 5, wherein the eotaxin-1 binding agent comprises a small molecule. ### Claim 8 (depends on 4) The method according to claim 4, wherein the active systemic eotaxin-1 reducing agent comprises an eotaxin-1 expression inhibitory agent. ### Claim 9 (depends on 8) The method according to claim 8, wherein the eotaxin-1 expression inhibitory agent comprises a nucleic acid. ### Claim 10 (depends on 1) The method according to claim 1, wherein eotaxin-1/CCR3 interaction is modulated by reducing CCR3 activity in the mammal. ### Claim 11 (depends on 10) The method according to claim 10, wherein the CCR3 activity is reduced in the mammal by administering to the mammal an effective amount of an active CCR3 reducing agent. ### Claim 12 (depends on 11) The method according to claim 11, wherein the active CCR3 reducing agent is a CCR3 binding agent. ### Claim 13 (depends on 12) The method according to claim 12, wherein the CCR3 binding agent comprises an antibody or binding fragment thereof. ### Claim 14 (depends on 12) The method according to claim 12, wherein the CCR3 binding agent comprises a small molecule. ### Claim 15 (depends on 11) The method according to claim 11, wherein the active CCR3 reducing agent comprises a CCR3 expression inhibitory agent. ### Claim 16 (depends on 15) The method according to claim 15, wherein the CCR3 expression inhibitory agent comprises a nucleic acid. ### Claim 17 (depends on 1) The method according to claim 1, wherein the mammal is a primate. ### Claim 18 (depends on 17) The method according to claim 17, wherein the primate is a human. ### Claim 19 (canceled) ### Claim 20 (depends on 1) The method according to claim 1, wherein the elderly mammal is a human that is 60 years or older. ### Claim 21 (depends on 1) The method according to claim 1, wherein the aging-associated impairment comprises a cognitive impairment. ### Claim at position 22 22-23. (canceled) ### Claim 24 (depends on 1) The method according to claim 1, wherein the adult mammal suffers from an aging associated disease condition. ### Claim 25 (depends on 1) The method according to claim 1, wherein the aging associated disease condition is a cognitive decline disease condition.